Keyword: Olivier Brandicourt
If you’re looking for new drama at Sanofi this year, you might just be disappointed. The French drugmaker said Wednesday it’s expecting no big financial swings and no big rush toward dealmaking in 2017.
Sanofi’s Olivier Brandicourt has said acquisitions will help the French drugmaker grow, but the CEO has been unable to pull off a major deal.
J&J abandoned its bid for Actelion Tuesday, but another buyer is talking with the Swiss biotech—and according to multiple media reports, Sanofi is it. Next question: At what cost success?
Sanofi has held firm on its M&A requirements since first quoting them last year: Bolt-ons all the way up to a buy a la its $20 billion Genzyme pickup. Would it make an exception for Actelion, now under pursuit by J&J for a reported $27 billion?
Amid slumping diabetes sales, Sanofi is shaking up its top management for the second time since CEO Olivier Brandicourt took over last year. Top diabetes and cardiovascular exec Pascale Witz is making an exit, and the beefed-up consumer unit will get a dedicated chief.